Ketamine Is Becoming Medicine and Contraband at the Same Time

Two press releases could have run side by side this year without anyone noticing the contradiction. One: a hospital in Toronto reports that ketamine, paired with talk therapy, brought meaningful pain relief to roughly 80% of chronic pain patients who got both — well above the 50-60% who got either alone. The other: the DEA emergency-scheduled a close chemical cousin of ketamine as a Schedule I drug, the same legal category as heroin, because it’s showing up in the illicit market and worrying regulators.

Same molecule family, two completely different verdicts, arriving at the same time.

Ketamine is being welcomed into the front door of mainstream psychiatry and locked out the back door as a street drug, simultaneously, and neither trend is slowing down for the other. If you’ve ever taken ketamine at a party, or you’re currently researching Spravato for depression that hasn’t responded to anything else, this isn’t an abstract policy story — it’s the actual, current shape of the drug you’re dealing with.

The medicine side: further into the front line

In January 2025, the FDA approved Spravato — the brand name for esketamine, a nasal-spray form of ketamine made by Johnson & Johnson — as the first standalone (“monotherapy”) treatment for adults with depression that hasn’t responded to other medications. Standalone matters here: before this approval, esketamine had to be prescribed alongside a daily oral antidepressant. Now a doctor can prescribe it by itself. More than 140,000 patients across 77 countries have now received it, and in the trial that won the monotherapy approval, 22.5% of patients were in remission at four weeks, compared with 7.6% on placebo — with some patients reporting relief within 24 hours, a timeline no standard antidepressant comes close to.

The newest data point lands somewhere Spravato was never designed to go. A pilot trial out of St. Michael’s Hospital at Unity Health Toronto, published this week in the journal Med, randomized 30 people with chronic nerve pain into three groups: ketamine alone, psychotherapy alone, or both together over 16 weeks. By 20 weeks, everyone improved somewhat — but only the combined group cleared 80% for clinically meaningful pain relief, against 50-60% in the single-treatment arms. Lead researcher Dr. Akash Goel described the population his team is working with plainly: “This is a novel treatment paradigm for a patient population that is suffering greatly.” Asked how he thinks the drug and the therapy work together, he reached for a gardening image rather than a pharmacology one: “Ketamine allows us to basically remove those weeds and plant new seeds for new flowers to grow.” He’s already lobbying for the next step — a multicenter trial across Canada, because, in his words, “the signals were really promising and strong enough.”

That’s the medicine side: a psychiatric monotherapy with a real approval and real remission numbers, and now early evidence it might help one of the hardest problems in medicine, chronic pain that hasn’t responded to anything else.

The market side: tighter enforcement, rising diversion, and a youth crisis nobody predicted this fast

Now the other direction. In 2026 the DEA moved to emergency-schedule 2-FDCK — a lab-made chemical cousin of ketamine, close enough in structure to produce similar effects — placing it in Schedule I, the government’s most restrictive category, reserved (on paper) for drugs judged to have no accepted medical use and high abuse potential. Ketamine itself hasn’t moved; it has sat in the more permissive Schedule III since 1999, the same category as anabolic steroids and some codeine products, precisely because it has decades of documented medical use behind it. Students for Sensible Drug Policy’s Kat Murti called the 2-FDCK move “drug policy by panic, not evidence,” warning it will “push people toward increasingly unregulated and unpredictable markets, increase the risk of adulteration and overdose” — the familiar pattern where banning an analog just pushes underground chemists toward the next, less-understood one.

Meanwhile the supply feeding the illicit market isn’t coming from clandestine labs at all — it’s coming from the legitimate pharmaceutical supply chain. A March 2026 EU Drugs Agency report traced Europe’s illicit ketamine mostly back to licensed manufacturing in India, imported in bulk for legal medical and veterinary use and then quietly diverted before it reaches a pharmacy. Seizures rose from roughly 200 kilograms in 2016 to more than 3.5 tonnes in 2024 — a scale increase the agency says has nothing to do with rising medical demand, which has stayed flat.

Meanwhile the supply feeding the illicit market isn’t coming from clandestine labs at all — it’s coming from the legitimate pharmaceutical supply chain.

And in England, the clinical fallout is arriving faster and younger than almost anyone forecast. Recreational use among 16-to-24-year-olds climbed from 0.8% in 2012/13 to a peak of 3.8% in 2022/23, then eased back to about 2.0% by 2024/25 — but treatment demand kept climbing through the decline, roughly twelvefold over ten years, because ketamine’s worst harm shows up on a delay. The drug can scar and shrink the bladder with repeated heavy use — a condition clinicians call “ketamine bladder” — and that damage often surfaces only after years of use, long after someone’s own use may have already tapered off. One Manchester treatment cohort makes the age of this crisis concrete: 64% of the ketamine patients that clinic is currently treating are under 18, and 42% are between 13 and 16. These aren’t abstract percentages on a slide — they’re teenagers, years from being legally able to buy a drink, already dealing with a chronic bladder condition that used to be described almost exclusively in adult recreational users.

The layer connecting both sides: nobody fully agrees on the safe dose

Here’s what keeps the medical and illicit stories from being two unrelated headlines: even inside psychiatry, the dosing question isn’t settled. A 2026 clinical review in the American Journal of Psychiatry, discussed at an American Society of Clinical Psychopharmacology panel, flagged real concern about neurotoxicity — brain-cell damage — tied to cumulative dose from frequent, off-label ketamine use, the kind some infusion clinics provide with far less oversight than Spravato requires. Even Spravato, delivered in a monitored clinical setting under a federally mandated safety program, causes sedation in 48-61% of patients in trials, with brief loss of consciousness in 0.3-0.4% — numbers regulators judged acceptable specifically because every dose happens under two hours of in-person observation. Take that same drug, or a lookalike bought online, without monitoring and at higher frequency, and the risk profile changes. The chemical doesn’t know whether it’s being administered in a monitored psychiatric suite or bought as a bag of powder — only the setting, dose, and frequency decide which story you end up in.

Ketamine has been here before — as someone else

This isn’t dissociatives’ first trip through this exact cycle. PCP, ketamine’s older and rougher cousin, was developed as a surgical anesthetic in the 1950s, prized because — unlike most anesthetics of the era — it didn’t suppress breathing. By the late 1960s it had leaked out of hospitals and into San Francisco’s counterculture as the “peace pill,” and its psychiatric side effects, which had already gotten it pulled from human medicine, turned uglier at street doses: agitation, violence, psychosis. Tabloids branded it “the most dangerous drug in America.” In 1978, on the strength of that reputation more than fresh clinical data, Congress moved PCP from the more permissive Schedule III straight to Schedule II — a legal demotion the drug never really recovered from. Ketamine was synthesized in 1962 specifically to be PCP’s gentler, shorter-acting replacement. Now it’s living through the exact same fork PCP hit in the 1970s — legitimacy on one side, panic on the other — except this time it’s happening to the same drug, in the same year, instead of one after the other.

What to actually do with this

If you’re the person weighing Spravato because nothing else has touched your depression, the FDA’s monotherapy approval and the remission numbers behind it are real and worth discussing with a psychiatrist — this is not the same product, dose, or setting as anything sold outside a clinic. And if you’re the person who’s used ketamine recreationally, or you’re not sure your use still counts as recreational, the England data is the part worth sitting with: the damage from heavy, frequent use often doesn’t announce itself until years later, which means feeling fine right now isn’t the same as being fine. Ketamine isn’t becoming safer or more dangerous in 2026. It’s becoming both, depending entirely on who’s holding it, how often, and under whose supervision — the same fork every dissociative in this class has faced since PCP first left the operating room. This time, medicine and the street aren’t taking turns. They’re happening to the same molecule, in the same year, to overlapping populations of people who deserve better than a system that treats one side as a triumph and the other as a footnote.